Glycopyrrolate Tablet
NDC Package 70752-109-10
Package Information
Glycopyrrolate tablets are indicated in adults to reduce symptoms of a peptic ulcer as an adjunct to treatment of peptic ulcer.Limitations of UseGlycopyrrolate tablets are not indicated as monotherapy for the treatment of peptic ulcer because effectiveness in peptic ulcer healing has not been established. This formulation utilizes a tablet delivery system. Marketed by Quagen Pharmaceuticals Llc, this product is identified by NDC 70752-109 and is authorized under FDA application ANDA212696.
Identification & Billing
- RxCUI: 197738 - glycopyrrolate 1 MG Oral Tablet
- RxCUI: 197739 - glycopyrrolate 2 MG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 70752 - Quagen Pharmaceuticals Llc
- 70752-109 - Glycopyrrolate
- 70752-109-10 - 100 TABLET in 1 BOTTLE, PLASTIC
- 70752-109 - Glycopyrrolate
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (70752-109). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 70752-109-10 identifies a specific commercial package of 100 tablet in 1 bottle, plastic of Glycopyrrolate, a human prescription drug labeled by Quagen Pharmaceuticals Llc. This tablet is formulated for oral use and contains glycopyrrolate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Quagen Pharmaceuticals Llc on October 10, 2024. The current certification is valid through December 31, 2026.
How is this Quagen Pharmaceuticals Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 70752010910. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.